Sector revisions Imunon, Inc.

Equities

Delayed Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
0.9131 ^USD	+1.68%		+1.47%	-3.88%

Dec. 19	IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	CI
Dec. 10	Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	CI

Sector:

Location:

X axis:

Main competitors

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Divergence of Estimates	Nbr of analysts
IMUNON, INC.	-		-		-		5
VERTEX PHARMACEUTICALS INCORPORATED							30
REGENERON PHARMACEUTICALS, INC.							25
ARGENX SE							16
BIONTECH SE							20
BEIGENE, LTD.							23
WUXI APPTEC CO., LTD.							17
NEUROCRINE BIOSCIENCES, INC.							24
SUMMIT THERAPEUTICS INC.	-	-	-	-	-	-	7
GENMAB A/S							16
INSMED INCORPORATED							16
SAREPTA THERAPEUTICS, INC.							21
VAXCYTE, INC.	-		-		-		9
EXELIXIS, INC.							22
WUXI BIOLOGICS (CAYMAN) INC.							25
CEREVEL THERAPEUTICS HOLDINGS, INC.	-		-		-		-
ASCENDIS PHARMA A/S							15
PHARMAESSENTIA CORPORATION							5
ZEALAND PHARMA A/S							11
AKESO, INC.							18
Average							17
Weighted average by Cap.							22